Exosome Therapy Bali | Nano Xsomes™ · Nano-PRP
Exosome Therapy Bali | Nano Xsomes™ · Nano-PRP
NANO XSOMES™ ARE MESENCHYMAL STEM CELL-DERIVED EXOSOMES — NANOSCALE EXTRACELLULAR VESICLES (30–150 NM) CARRYING BIOACTIVE CARGO INCLUDING GROWTH FACTORS (TGF-β, IGF-1, VEGF), MICRO-RNAs, AND ANTI-INFLAMMATORY MEDIATORS THAT MODULATE CELLULAR REPAIR, IMMUNE SIGNALLING, AND TISSUE REGENERATION WITHOUT THE RISK PROFILE OF DIRECT STEM CELL TRANSPLANTATION. DRIPDOK SOURCES ONLY ELISA-VERIFIED, US COLD-CHAIN EXOSOMES FROM GMP-CERTIFIED LABORATORIES WITH PEER-REVIEWED PRODUCT DOCUMENTATION.
Nano-PRP (Platelet-Rich Plasma, nanofiltered) is prepared from the patient’s own blood using a double-spin centrifuge protocol to concentrate platelet-derived growth factors (PDGF, TGF-β, EGF, FGF) at 5–10× baseline plasma levels. Nano-PRP can be administered IV, IM, or combined with exosome protocols for a synergistic regenerative cascade. Primary indications: post-injury tendon/joint repair, hair follicle regeneration, skin rejuvenation, systemic anti-ageing, and autoimmune modulation.
All exosome and PRP protocols require physician intake consultation. Exosome purity certificates and ELISA assay results are provided at request. Cold-chain delivery across Bali. Combined Nano Xsomes™ + Nano-PRP sessions represent Dripdok’s most advanced regenerative offering.
Session at a Glance
mL
IV
min
RN
Rx
24h
MD
SVC
From $2,500 USD
EXOSOME THERAPY — BALI
Nano Xsomes Bali | IV Exosome Therapy · Cellular Regeneration
Nano Xsomes — pharmaceutical-grade extracellular vesicles administered intravenously. A next-generation cellular signalling protocol targeting regeneration, neuroprotection, and immune modulation. Physician intake required. Nurse-administered across Bali.
Variable
Infusion volume per session
100%
Bioavailability via IV delivery
Variable
Typical session duration
EXOSOME DELIVERY PROTOCOL
US-Manufactured · Cold-Chain Verified · Sub-150nm
Each component is selected for physiological relevance and enzymatic function — not marketing appeal.
EV
Extracellular Vesicles (
Extracellular vesicles (30–150nm, sub-100nm NanoEx option) sourced from US-manufactured Allocyte and Matrix lines. Particle size determines pulmonary first-pass filtration bypass — sub-100nm particles demonstrate superior biodistribution in published preclinical data.
miRNA
Bioactive miRNA Cargo (Signalling Intact)
Bioactive miRNA cargo (miR-21, miR-146a, miR-126 among others) regulates gene expression at the target cell level — modulating inflammatory pathways, angiogenesis signals, and tissue repair cascades without altering nuclear DNA. Non-integrating, non-replicating.
GFs
Growth Factors (VEGF, PDGF, TGF-β)
Growth factors (VEGF, PDGF, TGF-β, IGF-1 analogues) carried within the exosome lumen stimulate receptor-mediated regenerative responses at the target tissue. Unlike exogenous growth factor injections, exosomal delivery is more physiologically controlled and sustained.
GSH
Glutathione Regular (Every Session)
Glutathione Regular (600mg) is included with every exosome session. GSH protects the infused exosomal cargo from oxidative degradation during administration and supports the anti-inflammatory environment required for optimal exosome-mediated signalling.
NS
0.9% Normal Saline (250 mL Carrier Base)
0.9% Normal Saline (250mL isotonic carrier). pH-balanced vehicle maintains exosome membrane integrity during infusion. Osmolality matched to physiological range — preserves vesicle structure and surface marker presentation critical for receptor binding.
CC
Cold-Chain −196°C (Maintained by Dripdok)
Cold-chain integrity is verified at every stage: US lab → Dubai → Bali. Dripdok maintains direct custody from arrival to administration. −196°C cryogenic storage on-site. Purity certificates and particle size reports available on request per vial.
CLINICAL BENEFITS
Targeted Cellular Mechanisms
Exosome therapy utilises extracellular vesicles — nano-scale lipid bilayer particles carrying bioactive cargo including miRNA, proteins, and signalling molecules — to modulate cellular behaviour across multiple tissue types. Intravenous delivery achieves systemic distribution, enabling regenerative signalling at the site of injury, inflammation, or cellular dysfunction.
01
Intercellular Signalling Restoration
Exosomes restore intercellular communication pathways disrupted by inflammation, ageing, or tissue damage. miRNA and protein cargo from MSC-derived exosomes modulate gene expression in target cells — re-establishing paracrine signalling gradients that drive tissue homeostasis.
02
Macrophage Polarisation M1→M2
MSC-derived exosomes shift macrophage polarisation from pro-inflammatory M1 to anti-inflammatory M2 phenotype. This mechanism is associated with reduced TNF-α, IL-6, and IL-1β — contributing to systemic anti-inflammatory effects observed across tissue types in preclinical and emerging clinical data.
03
Neuroinflammation Reduction
Exosomal miRNA and protein cargo modulate neuroinflammatory pathways by reducing microglial activation and NLRP3 inflammasome signalling. Early-stage research supports potential roles in post-viral neurological sequelae, age-related cognitive decline, and post-injury neuroprotection.
04
Tissue Regeneration via miRNA Transfer
Exosome-mediated tissue regeneration occurs via miRNA transfer that activates endogenous repair pathways — VEGF-driven angiogenesis, collagen synthesis, and fibroblast proliferation. Observed in musculoskeletal, dermal, and neural tissue contexts across multiple early-phase study designs.
PROTOCOL COORDINATION
How Each Session is Confirmed
01
Select Date, Time & Service
Submit your preferred service, date, and time. Your Patient Relations (PR) coordinator reviews availability and logistics — PR handles operational scheduling, not clinical decisions.
02
Secure Payment & Intake Form
A payment link is sent via Wise, Stripe, or local transfer. Advance payment is required to confirm the booking. Upon payment, you receive a patient consent and medical intake form to complete.
03
Physician Review & Confirmation
Your physician reviews the intake form for clinical suitability and safety. Once approved, your appointment is formally confirmed. Standard protocols require 24–48 hours advance notice for nurse scheduling and cold-chain preparation.
Begin Your Protocol
Physician-reviewed IV therapy, delivered to your location across Bali. Your Patient Relations team coordinates scheduling, payment, and confirmation. Standard protocols require 24–48 hours advance notice. Request your session below.
Begin Your Exosome Protocol
Physician-guided exosome therapy, delivered to your door. Available across Bali — Canggu, Seminyak, Ubud, Kuta, Nusa Dua, and surrounding areas. Physician intake assessment required prior to booking confirmation.
AT-HOME IV THERAPY — BALI
Nano Xsomes — Exosome IV Therapy
Next-generation extracellular vesicle therapy. Physician intake required. IV-administered across Bali — cellular regeneration via pharmaceutical-grade Nano Xsomes.
THE SCIENCE
Extracellular Vesicle Biology & Regenerative Signalling
Exosomes are extracellular vesicles (30–150 nm) secreted by cells as intercellular communication vehicles. They carry bioactive cargo — including microRNA, mRNA, proteins, and lipids — that modulates recipient cell gene expression, immune signalling, and regenerative activity. Nano Xsomes are pharmaceutical-grade preparations of exosomes derived from clinical-grade cell lines, standardised for particle count and cargo integrity. Intravenous administration allows systemic distribution with documented uptake in neural, immune, and musculoskeletal tissue.
WHAT'S INSIDE
Nano Xsomes Exosome Composition
Exosome Vial
Allocyte or Matrix Exosomes (US-manufactured) · 3–6 trillion particles per vial (1–2mL) · Sub-150nm particle size · NanoEx
Extracellular Vesicle Cargo
Bioactive miRNA cargo · Growth factors (VEGF, PDGF, TGF-β) · Anti-inflammatory cytokines (IL-10, TGF-β1) · Regenerative signalling proteins · Exosomal surface markers CD9, CD63, CD81 — integrity verified at administration
Delivery & Adjunct Protocol
0.9% Normal Saline (250mL infusion base) · Glutathione Regular (GSH — antioxidant protection during infusion, included every session) · Physician oversight at administration · Cold-chain verified day of infusion
Component concentrations are clinically determined by protocol. Physician review is required prior to every session. Formulations may be adjusted based on individual intake assessment.
CLINICAL DATA
Not All Exosome Therapies Are Equivalent
Exosome therapy outcomes are highly dependent on preparation, storage, administration route, and clinical oversight. The matrix below compares key delivery factors across three approaches.
| Factor | Dripdok | Standard Clinic | Oral / Topical |
|---|---|---|---|
| Exosome particle source | Pharmaceutical-grade, verified | Varies by supplier | Unverified / plant-derived |
| Cold chain integrity | Maintained end-to-end | Often unverified | Not applicable |
| Physician oversight | Every case reviewed | Inconsistent | None |
| Bioavailability route | IV — direct systemic delivery | IV or local injection | Degraded by GI tract |
| Particle count transparency | Declared and verifiable | Rarely disclosed | Not applicable |
Directional representation based on published literature and product category norms. Individual clinic practices vary. Not a clinical trial result.
INSIGHT
Exosomes don't deliver their cargo by rupturing — they transfer it. The distinction matters more than most patients realise.
A 2024 study in a major cell biology journal clarified an important mechanistic point about exosomal RNA delivery: unlike earlier gene therapy approaches, exosomal miRNA cargo is not released by membrane disruption. Instead, it enters target cells via endocytic pathways — meaning the protective lipid bilayer of the exosome remains intact until the cargo is already inside the cell. This offers a degree of protection from degradation that conventional RNA or peptide therapies cannot replicate.
The clinical implication is stability: miRNA cargo that survives the transport phase is significantly more likely to reach the target compartment at meaningful concentrations. This is one reason why exosome quality control — specifically particle integrity at the point of administration — is not a minor logistical detail. It is a determinant of whether the mechanism can operate at all.
CLINICAL INDICATION
Protocol Suitability
01
Accelerated Tissue Repair & Musculoskeletal Recovery. Individuals with joint degeneration, sports injuries, or post-surgical tissue repair requirements. Exosome signalling promotes chondrogenic differentiation and anti-inflammatory cytokine modulation in musculoskeletal tissue. Physician assessment required to confirm suitability.
02
Neurological Regeneration & Neuroprotection. Post-viral neurological sequelae, age-related cognitive decline, and neurodegenerative risk profiles. Exosomal miRNA cargo has demonstrated roles in BDNF upregulation, neuroinflammation reduction, and synaptic plasticity modulation in published preclinical and early clinical research.
03
Anti-Ageing & Systemic Cellular Rejuvenation. Advanced longevity candidates seeking cellular signalling-level intervention beyond micronutrient and NAD+ protocols. Exosome therapy represents the current frontier of regenerative medicine available outside hospital-based clinical trials. Strict physician intake protocol applies.
CLINICAL OUTCOMES
Observed Treatment Responses
Tissue Repair & Regeneration
Exosome-mediated delivery of regenerative miRNA and growth factors has been associated with accelerated tissue repair, reduced inflammatory markers, and chondrocyte and fibroblast activation in treated areas. Individual outcomes depend on baseline tissue status and dosing protocol.
Neurological Function & Neuroprotection
Clinical observations and emerging research support roles for exosome therapy in reducing neuroinflammation, improving cognitive recovery post-viral illness, and supporting synaptic function. BBB permeability of exosomal cargo enables CNS-relevant therapeutic action not achievable with conventional IV compounds.
Immune Modulation & Systemic Recovery
Exosomal signalling molecules modulate macrophage polarisation toward anti-inflammatory M2 phenotypes, support regulatory T-cell function, and reduce systemic pro-inflammatory cytokine expression. Reported outcomes include immune normalisation, systemic fatigue reduction, and improved recovery trajectory. All outcomes are individual and vary by clinical indication.
Clinical outcomes are individual and may vary based on baseline nutritional status, health history, and protocol frequency. These are reported observations, not therapeutic guarantees. This protocol does not constitute medical treatment for any specific condition. All sessions are physician-reviewed for safety and clinical appropriateness prior to confirmation.
PROTOCOL DESIGN
Extend the Exosome Advantage
Exosome therapy works best within a primed cellular environment. Pair it with protocols that optimise mitochondrial function, cognitive resilience, or neurological recovery for amplified results.
UPGRADE YOUR PROTOCOL
NeuroRestore IV + Exosomes
Combine exosome therapy with the NeuroRestore IV protocol for a dual-mechanism approach: exosomal miRNA cargo addresses signalling and tissue communication, while NeuroRestore's neurotrophic and anti-inflammatory substrates prepare the receiving environment. Each mechanism enhances the other's efficacy.
View NeuroRestore IVPAIR WITH
Methylene Blue IV
Methylene Blue acts at the mitochondrial level as an electron carrier — supporting the energy substrate that cells require to process and respond to exosomal signals. Pairing MB IV with exosome therapy targets both the communication signal and the energetic capacity to respond to it.
Explore Methylene Blue IVCOMPARABLE OPTION
NeuroRestore IV
If exosome therapy is outside your current scope, the NeuroRestore IV protocol delivers neurotrophic support, oxidative stress reduction, and neuroinflammation modulation through pharmaceutical-grade IV micronutrients — addressing many of the same recovery targets through a different biological route.
View NeuroRestore IVWHY DRIPDOK
A Physician-Founded System. Not an IV Menu.
DripDok was established in 2017 by a US-trained physician with academic foundations in molecular genetics, analytical chemistry, and biotechnology — and is associated with research through Purdue, Harvard, MIT, and Michigan State University. As the first clinic in Southeast Asia to offer advanced NAD+ IV protocols, DripDok operates as a precision medicine system, not a retail infusion bar. Every protocol is governed by diagnostic-first methodology, cold-chain sourcing standards, and formal physician oversight — applied to every client, every session.
PERSONALISED PROTOCOL
Exosome Therapy Requires a Physician Intake. Here's Why.
Unlike foundational IV protocols, exosome therapy at Dripdok is only administered after a physician intake with Dr. Close. This is not a formality — it guides preparation strategy, identifies whether additional protocols should precede or follow the exosome infusion, and ensures the biological environment is appropriate for treatment. Your clinical history directly informs outcome.
Dr. Close reviews all intake forms personally. Consultations are conducted via teleconsult or in person in Bali.
BEGIN YOUR PROTOCOL
How to Book a Session
Your Patient Relations team coordinator reviews your request and sends a secure payment link via Wise, Stripe, or local transfer. After payment, you complete a medical intake and consent form. Your physician reviews it for clinical suitability, then confirms your appointment. Standard protocols require 24–48 hours advance notice for nurse scheduling and cold-chain preparation.